Pharma & Biotech Insights, Interviews & Features
Biotechnology
11 November 2024 11 November 2024
Today's issue
Refine Search
Biotechnology
The first of a series of Industry Leader pieces from biological reagent supplier and service provider Sino Biological. 20 January 2022
Pharmaceutical
Stephen Page, founder and chief executive of Page & Page, provides an Expert View on the need for bolder communications in 2022. 14 January 2022
Pharmaceutical
India's Bharat Biotech has sought full market approval for its COVID-19 vaccine, Covaxin, from the country’s drug regulator. The indigenous Covaxin was approved on January 3, 2021, in emergency-use authorization (EUA) mode and has been administered to millions of people across India, including children, reports The Pharma Letter’s local correspondent. 14 January 2022
Pharmaceutical
The Russian government will consider increasing funding of “Circle of Kindness,” the national public foundation specializing on the procurement of drugs for the treatment of children with rare diseases, reports The Pharma Letter’s local correspondent. 13 January 2022
Pharmaceutical
A new draft government decree, which was developed by Russia’s Ministry of Industry and Trade, will restrict state purchases of drugs against some serious diseases, among which are HIV, oncology, diabetes and tuberculosis and will lead to their shortage in the Russian market, according to recent statements by representatives of the All-Russian Union of Patients (ARUP), one of Russia’s leading public associations representing interests of patients, reports The Pharma Letter’s local correspondent. 5 January 2022
Pharmaceutical
Adrian Tombling, partner and life sciences sector specialist at European intellectual property firm, Withers & Rogers, offers an Expert View on why patents are not the real barrier and why we need them to guard the human race against the risks posed by COVID-19 mutations or future pandemics. 4 January 2022
Pharmaceutical
As another wave of coronavirus infections swamp India, the country has stepped up its efforts to fight the disease and has cleared two new vaccines and one anti-COVID drug for restricted use. 2 January 2022
Biotechnology
Ever increasing investments are being made in artificial intelligence, as drugmakers spy an opportunity to drive efficiencies and spur innovation. In this episode, we discuss an exciting new collaboration between pharmaceutical majors in the field of AI. 30 December 2021
Pharmaceutical
The Russian Ministry of Health has officially presented a draft federal program to combat mortality from hepatitis C in Russia – a state program, adoption of which has been lobbied for by the patient community in Russia since 2011, reports The Pharma Letter’s local correspondent. 29 December 2021
Biosimilars
With the recent launch of the Avastin (bevacizumab) biosimilar in China, Henlius, the biotech arm of Fosun Pharma, now has four biosimilars under its belt. However, the Shanghai-based firm is eager to shake off the image of a biosimilars supplier. 22 December 2021
Biotechnology
The Russian Ministry of Health has approved the use of Zolgensma (onasemnogene abeparvovec), the world’s most expensive drug against spinal muscular atrophy (SMA) in the domestic market, reports The Pharma Letter’s local correspondent. 22 December 2021
Pharmaceutical
Russia is faced with a significant delay of drug supplies to the domestic market, as producers delay signing of contracts with the local state in an attempt to make a deal with higher prices for them, according to a recent report published by the Institute of State and Municipal Administration of the Higher School of Economics (ISMU), one of Russia’s leading research institutions in the field of finance, reports The Pharma Letter’s local correspondent. 22 December 2021
Biotechnology
In March 2021, the US Food and Drug Administration (FDA) announced its continued support for rare disease programs.1 So far, giant strides have been made in the search to find cures for diseases that affect a small percentage of the population, but are devastating in effect. 21 December 2021
Pharmaceutical
The year 2021 saw the US Food and Drug Administration approval of 46 novel drugs,1 80 first generics,2 two biosimilars,3 and nine novel biologics,4 as of December 10, 2021. In addition to the regulatory approval of therapeutics, the FDA has been addressing many other pressing public health concerns. We take a brief look at some of the FDA’s activities this year. 18 December 2021
Pharmaceutical
Jürgen Polifka, Director of Global Market Access at Advanz Pharma, provides a Special Report on the company's approach to securing rapid access for essential medicines. 17 December 2021
Pharmaceutical
The Russian drugmaker R-Pharm topped the rating of pharmaceutical manufacturers in Russia that made the biggest profits from public procurements of anti-COVID-19 drugs by the state for first 10 months of the current year, according to a recent study conducted by DSM Group, one of Russia’s leading analyst agencies in the field of pharmaceuticals, reports The Pharma Letter’s local correspondent. 15 December 2021
Biotechnology
In August 2020, Russia approved its homegrown coronavirus vaccine Sputnik V, months ahead of rival programs in the west. Episode 8 of The Pharma Letter Podcast features Kirill Dmitriev, chief executive of the vaccine's backer, RDIF. 14 December 2021
Pharmaceutical
Real world evidence (RWE) continues to grow as a promising frontier in evidence generation to support positive health outcomes. It can be useful in evaluating unmet healthcare needs, real world standard of care, and patient-reported outcomes, as well as developing realistic trial designs and budget impact models. 13 December 2021
Pharmaceutical
Virtually every drugmaker with a presence in hematology is preparing for their end-of-year attempt to impress physicians and investors with the best of their freshest data at the American Society of Hematology (ASH) Annual Meeting and Exposition. 10 December 2021
Generics
Supply chain disruptions, quality concerns and abrupt price hikes have been some of the issues resulting from over-dependency on a single source for supplies of life-saving drugs and other key raw materials. To mitigate risks associated with over-dependency on other nations, India's Health Minister Mansukh Mandaviya says the focus is to build self-reliance and promote the domestic pharmaceutical manufacturing industry, despite the decision to shut down two pharma public sector undertakings and disinvest three others, reports The Pharma Letter’s India correspondent. 9 December 2021
Biotechnology
This week, we discuss a novel AI-driven approach to drug development, and its potential to transform the treatment of cancer and autoimmune diseases. 14 November 2024
Biotechnology
An Expert View from Cumulus Oncology about its innovative business model, which is all about improving the efficiency of drug R&D. 11 November 2024
Generics
Indian drugmaker Aurobindo Pharma has taken on the might of China in terms of Penicillin G pricing, and is doing so by leveraging a fully integrated production process at its new plant. Anticipating the price erosion of Penicillin G, the company has put up an integrated plant from scratch. 10 November 2024
Pharmaceutical
Life science investors can be divided into two groups: those who bought Novo Nordisk stock before GLP-1s hit the big time, and those who wish they had. 10 November 2024
Generics
Indian markets are abuzz with a singular refrain. Donald Trump's Presidency of the United States is set to open new opportunities for India, especially in the pharmaceutical sector. 8 November 2024
Biotechnology
According to UNICEF's State of the World's Children 2023 report, in Latin America
and the Caribbean, 6.8 million children did not benefit from vaccination during the
time of the pandemic and in the following two years, progress has not been as
expected either. 7 November 2024
Biotechnology
As India's bioeconomy soars to a remarkable valuation of $151 billion, the government's Biotechnology Industry Research Assistance Council (BIRAC) has underscored the critical need for innovation and private sector investment to unlock further growth. 21 October 2024
Pharmaceutical
An Expert View from Nick Petschek, Managing Director EMEA, Kotter International. 18 October 2024
Biotechnology
Where once the state of play in the cell and gene therapy space was mostly limited to hope and hype around what might be to come, this is increasingly being replaced by action, on-market therapies and genuine expectation of reaching patients—provided companies can avoid some of the sector’s notorious pitfalls. 16 October 2024
Biotechnology
Antibody-drug conjugates (ADCs) represent a transformative class of cancer therapy that combine the targeting ability of antibodies with the cell-killing potential of cytotoxic drugs. 15 October 2024
Biotechnology
At last month’s European Academy of Dermatology and Venereology (EADV) congress in Amsterdam, Novartis presented new early and long-term Phase III data for remibrutinib in chronic spontaneous urticaria (CSU). 14 October 2024
Biotechnology
India's new Biotechnology Research Innovation and Entrepreneurship Development (Bio-RIDE) scheme is a significant step towards consolidating and advancing the country's biotechnology initiative. 7 October 2024
Pharmaceutical
F2G’s September $100m funding round provides the company with crucial funds to
renavigate approval of its lead drug, olorofim. The substantial financing also
highlights the paucity of novel antifungal products in the clinic. 3 October 2024
Pharmaceutical
Timing can be crucial in biotech, and any company that can help optimize radiopharmaceuticals to fight cancer is likely to a hot property right now, given the recent popularity of the field among investors and drugmakers. 2 October 2024
Pharmaceutical
As stakeholders in the pharmaceutical industry, we all have a responsibility to ensure life-saving treatments promptly and safely reach patients regardless of where they live. To this end, by integrating early access programs and other less conventional strategies into a company’s business model for drug distribution, patients who are suffering from life-threatening conditions can gain access to needed treatments in regions where there is a lack of drug accessibility, while at the same time offering benefits to pharmaceutical companies. 2 October 2024
Pharmaceutical
The Russian government has finalized the rules for granting preference to domestic drugs in public procurements, which will come into force in 2025. 1 October 2024
Pharmaceutical
A Feature on M&A, licensing and partnerships hotting up in inflammatory diseases as new targets present new opportunities for future growth. 30 September 2024
Pharmaceutical
India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
Generics
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical
Scarcely anything unites lawmakers in America these days, but the ostensible iniquities of Big Pharma could be a rare exception. 22 September 2024
Sign up to receive email updates
Join industry leaders for a daily roundup of biotech & pharma news
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze